Vitamin D and Respiratory Tract Infections: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

PLoS ONE
Q1
Jun 2013
Citations:380
Influential Citations:15
Systematic Reviews / Meta-Analyses
90
S2 IconPDF Icon

Enhanced Details

Methods
Randomized, placebo-controlled trials; 11 studies; 5660 participants; mean age 16 years; age range 6 months - 75 years; ~50% male; included healthy individuals and patients with RTI-related conditions.
Intervention
Oral vitamin D3 (cholecalciferol) supplementation; regimens varied across trials: daily doses typically around 400–2000 IU/day (average ~1600 IU/day); bolus regimens included 100,000 IU given at intervals such as every 4 weeks or every 3 months; duration varied across studies (months).
Results
Vitamin D supplementation reduces RTI risk. Pooled odds ratio 0.64 (95% CI 0.49 to 0.84). Daily dosing showed stronger protection (OR 0.51; 95% CI 0.39 to 0.67) than bolus dosing (OR 0.86; 95% CI 0.62 to 1.20). NNT to prevent one RTI over about 3 months ranged from 9 to 33. Results should be interpreted with caution due to heterogeneity across studies and potential publication bias; further research is needed to optimize dosing regimens and target populations.
Limitations
Significant heterogeneity across trials (I^2 72%); possible publication bias; varied dosing regimens and populations; some trials at high risk of bias; reliance on trial-level data.

Abstract

Background Low levels of 25-OH vitamin D are associated with respiratory tract infection (RTI). However, results from randomized controlled trials are inconclusive. Therefore, we performed a systematic review and meta-analysis to assess the preventiv...